ClinicalTrials.gg
CompletedNCT07630701Updated Jun 5, 2026

Inverted Periosteal Flap vs Buccal Advancement Flap for Oroantral Communication Closure

An interventional study of Inverted Buccal Periosteal Flap and Buccal Advancement Flap in Oroantral Communication, sponsored by Arab International University. Completed at 1 site in Syria. Open to participants aged 24 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by Arab International University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Sep 2024, registered Jun 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
24 Years to 50 Years
Sex
All
01

Study summary

This randomized controlled clinical study will evaluate the effectiveness of the inverted buccal periosteal flap in closing recent post-extraction oroantral communications and compare it with the conventional buccal advancement flap. The study will include 24 patients who develop an oroantral communication measuring 3-6 mm after non-surgical extraction of maxillary posterior teeth. Participants will be randomly allocated into two groups: the test group treated with the inverted buccal periosteal flap, and the control group treated with the buccal advancement flap. The primary outcome will be successful clinical closure of the communication, assessed by absence of oroantral fistula, nasal fluid leakage, and air leakage during the Valsalva test. Secondary outcomes will include postoperative pain, facial edema. Patients will be followed for up to 45 days after surgery.

Read the detailed description

Oroantral communication is an abnormal connection between the oral cavity and the maxillary sinus, most commonly occurring after extraction of maxillary posterior teeth. If not closed properly, it may lead to oroantral fistula or maxillary sinus complications.

This randomized controlled clinical study will compare the inverted buccal periosteal flap with the conventional buccal advancement flap for closure of recent post-extraction oroantral communications. The study will include 24 patients with communications measuring 3-6 mm and diagnosed within 48 hours after non-surgical extraction.

Participants will be randomly divided into two groups. In the test group, closure will be performed using the inverted buccal periosteal flap, where the periosteal layer is dissected, inverted over the defect, and sutured to the palatal tissue without tension. In the control group, closure will be performed using the buccal advancement flap, where a buccal mucoperiosteal flap is advanced palatally and sutured to cover the communication.

02

Conditions studied

  • Oroantral Communication

Keywords

  • Inverted buccal periosteal flap
  • Buccal advancement flap
  • Oral and maxillofacial surgery
  • Maxillary sinus
  • Surgical closure
03

In context

Lead sponsor

Arab International University is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
24 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Presence of an oroantral communication (OAC) with a diameter between 3-7 mm.
  2. Communication resulting from extraction of posterior maxillary teeth (first molar, second molar, third molar, or second premolar).
  3. Recent perforation occurring no more than 48 hours prior to surgical intervention.

Exclusion criteria

Exclusion Criteria:

  1. Presence of foreign bodies or residual tooth fragments within the maxillary sinus.
  2. Presence of systemic diseases that could impair wound healing (e.g., uncontrolled diabetes, ).
  3. History of maxillary sinusitis prior to the perforation.
  4. Presence of periapical lesions or cysts at the extraction site.
  5. Smokers.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Inverted Buccal Periosteal Flap

    Participants in this arm will receive surgical closure of the post-extraction oroantral communication using the inverted buccal periosteal flap. A full-thickness mucoperiosteal flap will be elevated, the periosteal layer will be dissected and inverted over the defect, then sutured to the palatal tissue to achieve tension-free closure.

    Procedure: Inverted Buccal Periosteal Flap

  • Active comparator
    Buccal Advancement Flap

    Participants in this arm will receive surgical closure of the post-extraction oroantral communication using the conventional buccal advancement flap. A buccal mucoperiosteal flap will be elevated, advanced palatally, and sutured to the palatal mucosa to cover the communication.

    Procedure: Buccal Advancement Flap

Interventions

  • ProcedureInverted Buccal Periosteal Flap

    Surgical closure of post-extraction oroantral communication using an inverted buccal periosteal flap. A full-thickness mucoperiosteal flap will be elevated, followed by dissection of the periosteal layer from the overlying mucosa. The periosteal flap will then be inverted over the defect and sutured to the palatal tissue to achieve tension-free closure.

  • ProcedureBuccal Advancement Flap

    Surgical closure of post-extraction oroantral communication using the conventional buccal advancement flap. A buccal full-thickness mucoperiosteal flap will be elevated, released by periosteal scoring, advanced palatally, and sutured to the palatal mucosa to cover the communication.

06

What researchers measure

Primary outcomes

  1. Successful Closure of Oroantral Communication

    Successful closure will be assessed clinically by confirming the absence of oroantral fistula formation, absence of fluid leakage through the nose, and absence of air leakage or air bubbles during the Valsalva test.

    Time frame: 1 week, 15 days, and 45 days after surgery.

Secondary outcomes

  1. Postoperative Pain

    Postoperative pain will be assessed using the Visual Analog Scale. The scale ranges from 0 to 10, where 0 indicates no pain and 10 indicates the worst possible pain. Higher scores indicate a worse outcome.

    Time frame: Postoperative days 1, 3, 5, and 7.

  2. Postoperative Facial Edema

    Facial edema will be assessed using extraoral linear measurements between fixed facial reference points. The measured distances will be used to estimate postoperative facial swelling and compare changes between the two study groups. Higher values indicate greater facial edema and therefore a worse outcome.

    Time frame: Postoperative days 1, 3, and 5.

07

Study locations

1 site
  • School of Dental Medicine
    Damascus, Syria
08

References and documents

Publications

  • Visscher SH, van Minnen B, Bos RR. Closure of oroantral communications: a review of the literature. J Oral Maxillofac Surg. 2010 Jun;68(6):1384-91. doi: 10.1016/j.joms.2009.07.044. Epub 2010 Mar 12. No abstract available. PubMed 20227153 ↗
  • Parvini P, Obreja K, Begic A, Schwarz F, Becker J, Sader R, Salti L. Decision-making in closure of oroantral communication and fistula. Int J Implant Dent. 2019 Apr 1;5(1):13. doi: 10.1186/s40729-019-0165-7. PubMed 30931487 ↗
  • Lago-Mendez L, Diniz-Freitas M, Senra-Rivera C, Gude-Sampedro F, Gandara Rey JM, Garcia-Garcia A. Relationships between surgical difficulty and postoperative pain in lower third molar extractions. J Oral Maxillofac Surg. 2007 May;65(5):979-83. doi: 10.1016/j.joms.2006.06.281. PubMed 17448851 ↗
  • Rosenfeld EA. Inverted periosteal flap: an alternative to the buccal advancement flap for tension-free, watertight closure. J Oral Maxillofac Surg. 2014 Jul;72(7):1244-50. doi: 10.1016/j.joms.2014.03.006. Epub 2014 Mar 20. PubMed 24768423 ↗
  • Ibrahim MT, Gharieb EA, Sheta MS. A pedicled buccal periosteal flap for the closure of oro-antral fistula. BMC Oral Health. 2024 Apr 10;24(1):440. doi: 10.1186/s12903-024-04217-6. PubMed 38600501 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2024 to primary completion in Aug 2025, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2026
First posted
Jun 5, 2026
StartActual
Sep 15, 2024
Primary completionActual
Aug 8, 2025
CompletionActual
Dec 10, 2025
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07630701
Lead sponsor
Arab International University
Collaborators
Damascus University
Responsible party
Sponsor
First posted
Jun 5, 2026
Start date
Sep 15, 2024
Primary completion
Aug 8, 2025
Completion
Dec 10, 2025
Last update
Jun 5, 2026

Study contacts

Majd S Mohammad, DDs
principal investigator · Damascus University
Omar A Heshmeh, PhD
study chair · Damascus University
Saleh Al Kurdi, PhD
study director · Arab International University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion